BioVie Inc logo

BIVI

BioVie Inc

$3.2

Earnings Summary

Revenue
$0Mn
Net Profits
$-7.04Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

BioVie Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, BioVie Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

BioVie Inc’s net profit fell -135.25% since last year same period to $-7.04Mn in the Q1 2022. On a quarterly growth basis, BioVie Inc has generated -30.04% fall in its net profits since last 3-months.

Net Profit Margins:

BioVie Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, BioVie Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the BioVie Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.42
EPS Estimate Current Year
-0.42

Highlights

EPS Estimate Current Quarter:

BioVie Inc’s earning per share (EPS) estimates for the current quarter stand at -0.42 - a -35.48% fall from last quarter’s estimates.

EPS Estimate Current Year:

BioVie Inc’s earning per share (EPS) estimates for the current year stand at -0.42.

Key Ratios

Key ratios of the BioVie Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.28
Return on Assets (ROA)
-4.78
Return on Equity (ROE)
-14
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

BioVie Inc’s earning per share (EPS) fell -27.27% since last year same period to -0.28 in the Q1 2022. This indicates that the BioVie Inc has generated -27.27% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. BioVie Inc’s return on assets (ROA) stands at -4.78.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. BioVie Inc’s return on equity (ROE) stands at -14.

Dividend Per Share (DPS):

BioVie Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-11
-0.42
-0.28
33.33%

Company Information

BioVie Inc. is developing BIV201 (continuous infusion terlipressin) an Orphan Drug candidate for the treatment of ascites due to advanced liver cirrhosis. First-to-market Orphan therapies typically receive 7 years of market exclusivity in the US for the designated use(s). It is being investigated as a potential new therapy for patients suffering from ascites, and future development opportunities include hepatorenal syndrome (HRS) and other life-threatening complications of advanced liver cirrhosis. The initial disease target for BIV201 therapy is ascites, which is a serious complication of advanced liver cirrhosis. The Company has completed a Phase 2 clinical trial protocol that is summarized on www.clinicaltrials.gov, trial identifier NCT04112199. The FDA has never approved any drug specifically for treating ascites, and the Company is not aware of any competing drugs in late-stage development for ascites. The active agent in BIV201, terlipressin, is approved for use in about 40 countries for the treatment of related complications of advanced liver cirrhosis but is not available in the US or Japan. The Company has invented a patent-pending prefilled syringe that has been cleared for use in our upcoming Phase 2 trial subject to certain additional standard analytical tests. This novel BIV201 delivery system is expected to greatly simplify at-home patient treatment and improve patient compliance by enabling easy injection of the liquid concentrate into the IV bag connected to the infusion pump. Room temperature stability has been achieved for 9 months providing an important advantage because, to the best of the Company's knowledge, all other terlipressin products sold globally must be stored under refrigeration. The novel prefilled syringe format also avoids the manual mixing of minute (2 - 4 mg) quantities of terlipressin powder in saline solution, thereby reducing the possibility of dosing errors during reconstitution and improving sterility. BioVie has begun applying for global patent protection for this novel terlipressin delivery system. The Company has also received Orphan Drug designation for the treatment of hepatorenal syndrome (HRS) and has FDA Fast Track status.

Organisation
BioVie Inc
Employees
3
Industry
Biotechnology